BioSpyder Technologies

What BioSpyder Technologies does

BioSpyder Technologies is a Carlsbad, California-based life sciences tools company founded in December 2011 by Joel McComb (CEO), Joanne Yeakley (VP R&D), and Bruce Seligmann (CSO) that develops and commercializes TempO-Seq (Templated Oligo-Sequencing), a proprietary targeted sequencing platform for gene expression profiling. The platform uses template-dependent detector oligo ligation chemistry that interrogates RNA directly without requiring RNA extraction, cDNA conversion, or pre-amplification, enabling analysis of cell lysates, FFPE tissue, frozen tissue, dried blood spots, and miRNA inputs on standard PCR instruments or microplate incubators. The platform can multiplex up to 6,144 samples per sequencing run with 99% single-base mismatch specificity and supports panels covering human, mouse, rat, zebrafish, and EcoTox species.

The company's product portfolio includes the core TempO-Seq assay, pre-designed whole-transcriptome and S1500+ surrogate panels, TempO-LINC (single-cell, launched 2025), TempO-Seq miRNA (2,112 targets), TempO-Seq Dried Blood Spot, TempO-SPan (pathogen detection including SARS-CoV-2/Influenza/RSV), and the upcoming TempO-SNP genotyping assay. BioSpyder also operates the TempO-Seq Portal cloud analysis module and offers managed bioinformatics services including probe design, differential expression analysis, and machine learning classification. Revenue is generated through quote-based kit and panel sales, full-service sample processing projects with 4–6 week turnaround, and bioinformatics consulting.

BioSpyder targets four primary customer segments: pharmaceutical and biotech companies conducting early compound screening and drug development safety assessment, toxicology and environmental science researchers (including regulatory chemical safety), oncology research groups pursuing biomarker discovery, and academic/government genomics labs. Commercial distribution is direct in the USA and through regional distributors covering Scotland, Spain, South Korea, Japan, Hong Kong, Thailand, Singapore, and Malaysia. The company is privately held by its three co-founders with no disclosed institutional investors; R&D has been substantially supported by competitive NIH grants from NHGRI, NIEHS, NCATS, NCI, and NIFA/USDA, and its technology is protected by a broad international patent estate.

Name

BioSpyder Technologies

Legal name

BioSpyder, Inc.

Website

https://biospyder.com

Company type

Private

Founded year

2011

Operating status

Operating

Headcount range

11–50 employees

Short description

BioSpyder Technologies develops and commercializes TempO-Seq, a proprietary targeted sequencing platform for high-throughput gene expression profiling that bypasses RNA extraction. The Carlsbad, California company sells assay kits, panels, and full-service sequencing to pharmaceutical, toxicology, oncology, and academic researchers globally.

Ownership category

akta.pro rank

Product category

Genomics Assay Products

NAICS

Analytical Laboratory Instrument Manufacturing (334516), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical Laboratories (621511), In-Vitro Diagnostic Substance Manufacturing (325413), Software Publishers (5132)

SIC

Laboratory Analytical Instruments (3826), Services-Commercial Physical & Biological Research (8731), In Vitro & In Vivo Diagnostic Substances (2835), Services-Prepackaged Software (7372)

akta.pro primary industry

Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays) (HLAGAIAF)

akta.pro secondary industries

Transcriptomics & Gene Expression Profiling Services (HLAGANAE), Bioinformatics, Multi-Omics Data Analysis & Interpretation Services (HLAGANAI), Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics) (HLAAAMAJ), Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)

Keywords

• Gene expression profiling
• Targeted sequencing assays
• Single-cell transcriptomics
• Molecular diagnostics tools
• Bioinformatics analysis services

Headquarters

HQ city

Carlsbad

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure, Operations

Revenue model

1. TempO-Seq Kits and Panels: Sale of assay kits including whole transcriptome panels, S1500+ surrogate panels, and custom panels for human, mouse, rat, zebrafish, and EcoTox species. Customers can purchase panels directly and run assays in their own labs.
2. Service Projects: BioSpyder processes customer samples using TempO-Seq and TempO-LINC platforms. Service projects typically have 4-6 week turnaround. Deliverables include FASTQ files, count tables, and service reports.
3. Bioinformatics Services: Additional data analysis support including probe design, exploratory data analysis, differential gene expression analysis, machine learning classification, pathway analysis, and single-cell analysis.

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Core offering

BioSpyder develops and sells the TempO-Seq (Templated Oligo-Sequencing) targeted sequencing platform for gene expression profiling, offering assay kits and pre-designed panels (human, mouse, rat, zebrafish, EcoTox species) that customers run in their own labs, as well as fee-for-service projects (4–8 week turnaround) where BioSpyder processes customer samples and delivers FASTQ files, count tables, and analysis reports. The proprietary chemistry eliminates RNA extraction, cDNA conversion, and pre-amplification, supports multiplexing of up to 6,144 samples per run, and is complemented by the cloud-based TempO-Seq Portal and managed bioinformatics services.

Product overview

BioSpyder Technologies offers the TempO-Seq (Templated Oligo-Sequencing) platform as its core product — a targeted sequencing system for gene expression profiling that avoids RNA extraction, cDNA conversion, or pre-amplification through proprietary detector oligo ligation chemistry. The platform comprises multiple specialized sub-products: TempO-Seq (core targeted sequencing assay accepting diverse inputs), TempO-Seq Dried Blood Spot (blood-based transcriptomics), TempO-Seq miRNA (microRNA profiling), TempO-LINC (single-cell expression profiling service), TempO-SNP (SNP detection, upcoming), and TempO-SPan (pathogen/respiratory virus detection). These are complemented by the TempO-Seq Portal cloud analysis module and managed Bioinformatics Services for custom probe design, differential expression, machine learning classification, pathway analysis, and single-cell analysis. Pre-designed panels cover human, mouse, rat, zebrafish transcriptomes and EcoTox species. The platform is validated across applications in toxicology, oncology, pharma, computational biology, and agriculture.

Differentiator

Problem solved

Functional benefit

Brands

• TempO-Seq: Proprietary targeted sequencing platform for gene expression profiling using templated oligo detection chemistry, capable of analyzing hundreds to thousands of genes in high throughput.
• TempO-LINC
• TempO-SPan
• TempO-SNP
• TempO-Seq Portal

Products and services

• TempO-Seq TempO-Seq (Templated Oligo-Sequencing) is a targeted sequencing assay for gene expression profiling that monitors hundreds to thousands of genes in high throughput without RNA extraction, cDNA conversion, or pre-amplification. It uses proprietary detector oligo ligation chemistry, accepts diverse input types (cell lysates, FFPE tissue, frozen tissue, dried blood spots, miRNA), and enables pooling of up to 6,144 samples per run on standard PCR instruments or microplate incubators.
• TempO-Seq Dried Blood Spot A TempO-Seq variant that enables whole transcriptome profiling from dried whole blood or buffy coat samples on filter paper, collected by finger prick or venipuncture. Uses modified chemistry that maintains RNA integrity while eliminating unwanted signal from hemoglobin transcripts, and supports longitudinal studies because dried samples are stable for months.
• TempO-Seq miRNA A TempO-Seq-based assay for targeted, extraction-free measurement of miRNA expression across cell lines, FFPE tissues, plasma, and whole blood. The Human Whole miRNome panel includes 2,112 miRNA targets from miRBase v22.1 and supports custom panels for any species.
• TempO-LINC A single-cell gene expression profiling service derived from TempO-Seq that combines templated oligo ligation with combinatorial split-pool barcoding for transcriptome-wide measurements at single-cell resolution. Customers receive a Fixation Kit, ship fixed samples, and BioSpyder processes and sequences them, delivering data 6-8 weeks after sample receipt in formats compatible with Seurat and Scanpy.
• TempO-SPan A TempO-Seq variant for multiplexed detection of respiratory viruses, including SARS-CoV-2, Influenza A/B, and RSV. Supports up to 20 targets per panel, pools up to 6,144 samples per sequencing run, and includes automated calling software for patient reports. Custom detector oligo design enables additional pathogen targets.
• TempO-Seq Portal A cloud-based web portal for TempO-Seq data alignment, quality control, and differential expression analysis. Users upload FASTQ files for alignment against reference genomes and receive count tables, signal metrics per probe, PCA grouping, fold-change calculations, and correlation analysis through a GUI requiring no informaticist or installation.
• Bioinformatics Services Managed bioinformatics consulting covering all phases of a TempO-Seq experiment, including custom probe design for transcript isoforms, genomic regions, and SNPs/INDELs; exploratory data analysis (PCA, heatmaps); differential gene expression analysis; machine learning-based classification for biomarker discovery delivered as standalone or cloud Web applications; pathway and gene ontology analysis; and single-cell analysis including clustering, t-SNE/UMAP, and differential expression between cell types.
• TempO-Seq Panels Pre-designed TempO-Seq panels covering Human Whole Transcriptome, Human PanCancer, Human S1500+ Surrogate, Mouse Whole Transcriptome, Rat Whole Transcriptome, Zebrafish S1500+, and EcoTox species (Daphnia magna, Chironomus dilutus, Pimephales promelas, Raphidocelis subcapitata). All panels support custom content additions or subtractions without impact on other targets in the signature.
• TempO-Seq Service Projects A fee-for-service offering in which BioSpyder processes customer samples using TempO-Seq and TempO-LINC, delivering FASTQ files, count tables, and service reports with typical turnaround of 4-6 weeks for TempO-Seq and 6-8 weeks for TempO-LINC. Customers ship samples and BioSpyder handles assay execution, sequencing, and primary data delivery.

Quantifiable outcome

• Up to 6,144 samples multiplexed in single sequencing run
• +4 more outcomes

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability2 records

Feature6 records

Partnerships

13 partnerships are on record, tiered core and regional.

• National Institutes of Health (NIH)coreStrategic or Co-development PartnerNIH grants supporting TempO-Seq development from multiple institutes: National Human Genome Research Institute (NHGRI), National Institute of Environmental Health Sciences (NIEHS), and National Center for Advancing Translational Science (NCATS). Multiple completed grants including Alzheimer's disease research, single-cell profiling, genomic risk screening, and RNA epitranscriptomic modifications.
• National Human Genome Research Institute (NHGRI)coreStrategic or Co-development PartnerNHGRI funding for TempO-Seq Gene Expression Profiling Platform development and TempO-Seq for preserved tissues in toxicity and translational testing.
• National Institute of Environmental Health Sciences (NIEHS)coreStrategic or Co-development PartnerNIEHS funding for TempO-Seq applications in toxicology research including multiplexed mRNA and miRNA profiling of single cells.
• National Center for Advancing Translational Science (NCATS)coreStrategic or Co-development PartnerNCATS funding for TempO-LINC high throughput single cell gene expression profiling assay development.
• National Cancer Institute (NCI)coreStrategic or Co-development PartnerNCI contract (HHSN261201600059C) for cfNA TempO-Seq Assay development.
• NIFA/USDAcoreStrategic or Co-development PartnerUSDA funding for TempO-STAT Citrus Greening Infection Test (NIFA/USDA 2017-33610-26749).
• BioClavis Ltd.coreChannel Partner/ Reseller/ DistributorGlobal distributor for BioSpyder products. Based in Glasgow, Scotland. Handles distribution for Scotland and provides global coverage.
• Durviz S.LregionalChannel Partner/ Reseller/ DistributorRegional distributor for Spain. Based in Valencia, Spain.
• LAS CoregionalChannel Partner/ Reseller/ DistributorRegional distributor for South Korea. Based in Gimpo, Korea.
• AS-ONEregionalChannel Partner/ Reseller/ DistributorRegional distributor for Japan. Based in Osaka, Japan.
• ATCGregionalChannel Partner/ Reseller/ DistributorRegional distributor for Hong Kong. Based in New Territories, Hong Kong.
• Bang Trading 1992regionalChannel Partner/ Reseller/ DistributorRegional distributor for Thailand. Based in Bangkok, Thailand.
• Atlantis BioscienceregionalChannel Partner/ Reseller/ DistributorRegional distributor for Singapore and Malaysia. Based in Singapore.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Takara Bio: A direct competitor in gene expression profiling via SMARTer stranded RNA-Seq kits and NGS targeted panels. Overlaps with BioSpyder's TempO-Seq miRNA, whole-transcriptome, and bulk targeted RNA workflows across academic and translational research buyers.
• QIAGEN: A direct competitor in targeted NGS panels (e.g., QIAseq targeted RNA panels) serving pharma toxicology and molecular diagnostics customers. Overlaps with BioSpyder on reagent kits, panel design, and bioinformatics services for targeted RNA expression.
• 10x Genomics: A direct competitor in single-cell and targeted gene expression, particularly via Chromium and Visium platforms. TempO-LINC and BioSpyder's single-cell service offering compete with 10x's large-installed-base single-cell transcriptome workflows.
• HTG Molecular Diagnostics: A direct niche competitor offering the EdgeSeq targeted sequencing platform for gene expression profiling from limited/FFPE samples without RNA extraction. EdgeSeq directly competes with TempO-Seq in the same extraction-free, no-library-prep targeted sequencing category.
• Standard BioTools (formerly Fluidigm): A direct competitor in single-cell gene expression via the Hyperion / Imaging Mass Cytometry and original C1/Biomedical genomics platforms. Competes with TempO-LINC's high-throughput single-cell RNA profiling in toxicology and pharma research.
• NanoString Technologies: A direct competitor in targeted gene expression profiling with its nCounter platform and GeoMx digital spatial profiling. Both companies target toxicology, oncology, and pharma R&D buyers with multiplexed targeted RNA assays, and compete head-to-head for S1500+ adoption.

Broad incumbents

• Thermo Fisher Scientific: A broad incumbent offering Ion Torrent targeted NGS, Applied Biosystems TaqMan/qPCR panels, and full workflow solutions. Adjacent competitor across gene expression, transcriptomics, and clinical diagnostics markets where BioSpyder competes.
• Bio-Rad Laboratories: A broad incumbent offering ddSEQ single-cell expression, QX200 ddPCR, and various life science research tools. BioSpyder's CEO Joel McComb sits on Bio-Rad's board, signaling competitive overlap in droplet-based and targeted expression assays.
• Illumina: A broad incumbent dominating the sequencing market. BioSpyder's TempO-Seq reads out on Illumina sequencers and several founders (McComb, Yeakley) are ex-Illumina. Illumina's targeted RNA products and bundled reagent economics create pricing pressure on BioSpyder kits.
• Becton, Dickinson and Company (BD): A broad incumbent in clinical diagnostics and life sciences tools with growing single-cell and targeted expression offerings. Adjacent competitor through its biosciences and diagnostic solutions businesses that overlap with BioSpyder's pathogen detection and molecular profiling workflows.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BioSpyder Technologies